FR3109881B1 - Procede pour ameliorer le systeme immun pour acquerir la pan-immunite - Google Patents

Procede pour ameliorer le systeme immun pour acquerir la pan-immunite Download PDF

Info

Publication number
FR3109881B1
FR3109881B1 FR2004533A FR2004533A FR3109881B1 FR 3109881 B1 FR3109881 B1 FR 3109881B1 FR 2004533 A FR2004533 A FR 2004533A FR 2004533 A FR2004533 A FR 2004533A FR 3109881 B1 FR3109881 B1 FR 3109881B1
Authority
FR
France
Prior art keywords
extract
species
immunity
pan
acquire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2004533A
Other languages
English (en)
Other versions
FR3109881A1 (fr
Inventor
Saada Harti
Jiawei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Legacy Healthcare Switzerland SA
Original Assignee
Legacy Healthcare Switzerland SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2004533A priority Critical patent/FR3109881B1/fr
Application filed by Legacy Healthcare Switzerland SA filed Critical Legacy Healthcare Switzerland SA
Priority to CN202180033443.9A priority patent/CN115666525A/zh
Priority to EP21723282.6A priority patent/EP4146169A1/fr
Priority to MX2022013868A priority patent/MX2022013868A/es
Priority to JP2022567246A priority patent/JP2023529062A/ja
Priority to BR112022021695A priority patent/BR112022021695A2/pt
Priority to US17/922,884 priority patent/US20230270812A1/en
Priority to KR1020227041721A priority patent/KR20230007451A/ko
Priority to CA3177105A priority patent/CA3177105A1/fr
Priority to PCT/EP2021/062135 priority patent/WO2021224455A1/fr
Priority to AU2021267004A priority patent/AU2021267004A1/en
Publication of FR3109881A1 publication Critical patent/FR3109881A1/fr
Application granted granted Critical
Publication of FR3109881B1 publication Critical patent/FR3109881B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pour améliorer le système immunitaire pour acquérir la pan–immunité pour la prévention et les traitements des maladies infectieuses et autres maladies à composantes immunologiques, y compris éliminer les cellules cancéreuses. La composition comprend l’administration par des voies orales, parentérales, l’injection locale, l’application topique, ou en combinaison de celles–ci, ou l’administration comme adjuvant potentiateur dans diverses thérapies/divers traitements utilisant les voies précitées, d’une composition contenant comme ingrédient actif un extrait de l’espèce Allium, un extrait de l’espèce Citrus, et un extrait de l’espèce Paullinia et un extrait de l’espèce Theobroma.
FR2004533A 2020-05-07 2020-05-07 Procede pour ameliorer le systeme immun pour acquerir la pan-immunite Active FR3109881B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR2004533A FR3109881B1 (fr) 2020-05-07 2020-05-07 Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
CA3177105A CA3177105A1 (fr) 2020-05-07 2021-05-07 Composition pour renforcement du systeme immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunite globale
MX2022013868A MX2022013868A (es) 2020-05-07 2021-05-07 Composicion para utilizarse en el fortalecimiento del sistema inmunitario en seres humanos y animales para adquirir paninmunidad.
JP2022567246A JP2023529062A (ja) 2020-05-07 2021-05-07 ヒト及び動物において免疫系を強化して汎免疫性を獲得するために使用される組成物
BR112022021695A BR112022021695A2 (pt) 2020-05-07 2021-05-07 Composição a ser utilizada para fortalecer o sistema imune em humanos e animais para adquirir pan-imunidade
US17/922,884 US20230270812A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
CN202180033443.9A CN115666525A (zh) 2020-05-07 2021-05-07 用于增强人和动物免疫系统以获得多种免疫的组合物
EP21723282.6A EP4146169A1 (fr) 2020-05-07 2021-05-07 Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
PCT/EP2021/062135 WO2021224455A1 (fr) 2020-05-07 2021-05-07 Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
AU2021267004A AU2021267004A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
KR1020227041721A KR20230007451A (ko) 2020-05-07 2021-05-07 범-면역을 획득하기 위한 인간 및 동물의 면역 체계 강화에 사용되는 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2004533 2020-05-07
FR2004533A FR3109881B1 (fr) 2020-05-07 2020-05-07 Procede pour ameliorer le systeme immun pour acquerir la pan-immunite

Publications (2)

Publication Number Publication Date
FR3109881A1 FR3109881A1 (fr) 2021-11-12
FR3109881B1 true FR3109881B1 (fr) 2022-10-21

Family

ID=72644307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2004533A Active FR3109881B1 (fr) 2020-05-07 2020-05-07 Procede pour ameliorer le systeme immun pour acquerir la pan-immunite

Country Status (11)

Country Link
US (1) US20230270812A1 (fr)
EP (1) EP4146169A1 (fr)
JP (1) JP2023529062A (fr)
KR (1) KR20230007451A (fr)
CN (1) CN115666525A (fr)
AU (1) AU2021267004A1 (fr)
BR (1) BR112022021695A2 (fr)
CA (1) CA3177105A1 (fr)
FR (1) FR3109881B1 (fr)
MX (1) MX2022013868A (fr)
WO (1) WO2021224455A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912310B1 (fr) * 2007-02-13 2009-08-07 Kasan Sarl Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
CA2826235A1 (fr) * 2011-02-23 2012-08-30 Legacy Healthcare Ltd Nouvelle utilisation de compositions pour prevenir l'alopecie induite par chimiotherapie et radiotherapie (cria), reduire l'impact de la cria et ameliorer l'aspect de la repoussedes cheveux apres cria
WO2012140013A2 (fr) * 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène
EP2862598A1 (fr) * 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Utilisation d'une composition pour la pigmentation des cheveux et des poils
BR112016009931B1 (pt) * 2013-11-08 2021-02-02 Legacy Healthcare Ltd composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer
WO2017186954A1 (fr) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Procédé d'amélioration de la vitesse et de la capacité d'endurance

Also Published As

Publication number Publication date
US20230270812A1 (en) 2023-08-31
WO2021224455A1 (fr) 2021-11-11
CN115666525A (zh) 2023-01-31
CA3177105A1 (fr) 2021-11-11
BR112022021695A2 (pt) 2022-12-20
KR20230007451A (ko) 2023-01-12
AU2021267004A1 (en) 2022-12-15
JP2023529062A (ja) 2023-07-07
FR3109881A1 (fr) 2021-11-12
EP4146169A1 (fr) 2023-03-15
MX2022013868A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
MX2024000820A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
MA34470B1 (fr) Procédés et composés pour traiter des infections à virus paramyxoviridae
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
Lukan “Cytokine storm”, not only in COVID-19 patients. Mini-review
EA201100032A1 (ru) Соединения пиридина
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
EA201790740A1 (ru) Индолкарбоксамидные соединения
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BR112013017446A2 (pt) composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona
EA200900351A1 (ru) Ингибиторы тирозинкиназы брутона
EA201390310A1 (ru) Фармацевтические композиции, содержащие рифаксимин, способы их получения и способ лечения кишечного заболевания
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
MA38287A1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
FR3109881B1 (fr) Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
BR112022014968A2 (pt) Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade
Vaghasiya et al. Comparative evaluation of alcoholic and aqueous extracts of Ocimum sanctum for immunomodulatory activity
UA117046C2 (uk) [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ ПРОТОЗОЙНИХ ПРОТЕАСОМ ДЛЯ ЛІКУВАННЯ ПАРАЗИТАРНИХ ЗАХВОРЮВАНЬ, ТАКИХ ЯК ЛЕЙШМАНІОЗ
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
BRPI0519023A2 (pt) composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211112

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5